BioMarin Pharmaceuticals, Inc. (BMRN) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $64.73 --0%
Revenue Growth %: +32.7%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: +32.7%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported GAAP Q2 EPS of ($0.27), $0.06 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $124 million versus the consensus estimate of $121.54 million.
BioMarin Pharmaceuticals, Inc. sees FY2012 revenue of $475-$510 million, versus the consensus of $494.51 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
BioMarin Pharmaceuticals, Inc. sees FY2012 revenue of $475-$510 million, versus the consensus of $494.51 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
- Intuit holds investor day, reaffirms fiscal 2027 guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
